{"id":"https://openalex.org/W2367051944","doi":null,"title":"Clinical effect and pharmacoeconomics of gefitinib and erlotinib in advanced non-small-cell lung cancer","display_name":"Clinical effect and pharmacoeconomics of gefitinib and erlotinib in advanced non-small-cell lung cancer","publication_year":2009,"publication_date":"2009-01-01","ids":{"openalex":"https://openalex.org/W2367051944","mag":"2367051944"},"language":"en","primary_location":{"id":"mag:2367051944","doi":null,"is_oa":false,"landing_page_url":"https://en.cnki.com.cn/Article_en/CJFDTotal-XYYL200911012.htm","pdf_url":null,"source":{"id":"https://openalex.org/S2764853906","display_name":"Chinese Journal of New Drugs and Clinical Remedies","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4323986928","host_organization_name":"Zhongguo Yao Xuehui Shanghai Fenhui","host_organization_lineage":["https://openalex.org/P4323986928"],"host_organization_lineage_names":["Zhongguo Yao Xuehui Shanghai Fenhui"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Chinese Journal of New Drugs and Clinical Remedies","raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101438099","display_name":"Xiaoqing Zhang","orcid":"https://orcid.org/0000-0003-2045-2138","observed_orcids":["https://orcid.org/0000-0003-2045-2138"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Xiaoqing Zhang","raw_affiliation_strings":["a, LI Yu-ping1a, NI Jian1b, LIU Gao-lin2"],"raw_orcid":"https://orcid.org/0000-0003-2045-2138","affiliations":[{"raw_affiliation_string":"a, LI Yu-ping1a, NI Jian1b, LIU Gao-lin2","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5101438099"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.39122762,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":1.0},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":1.0},{"id":"https://openalex.org/keywords/advanced-non-small-cell-lung-cancer","display_name":"advanced non-small cell lung cancer","score":0.9440000057220459},{"id":"https://openalex.org/keywords/pharmacoeconomics","display_name":"pharmacoeconomics","score":0.7639999985694885},{"id":"https://openalex.org/keywords/adverse-effects","display_name":"adverse effects","score":0.5370000004768372},{"id":"https://openalex.org/keywords/time-to-progression","display_name":"time to progression","score":0.781000018119812},{"id":"https://openalex.org/keywords/survival","display_name":"survival","score":0.5950000286102295},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.7910000085830688},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.8560000061988831}],"concepts":[{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.9852249622344971},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.9732418060302734},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8194286823272705},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.7733175158500671},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6015197038650513},{"id":"https://openalex.org/C2909325608","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib Hydrochloride","level":5,"score":0.5733919143676758},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5187042355537415},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5182549953460693},{"id":"https://openalex.org/C2776738588","wikidata":"https://www.wikidata.org/wiki/Q1567856","display_name":"Pharmacoeconomics","level":2,"score":0.5120930671691895},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.3764834403991699},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3681594133377075},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2671155333518982},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.1468428671360016}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2367051944","doi":null,"is_oa":false,"landing_page_url":"https://en.cnki.com.cn/Article_en/CJFDTotal-XYYL200911012.htm","pdf_url":null,"source":{"id":"https://openalex.org/S2764853906","display_name":"Chinese Journal of New Drugs and Clinical Remedies","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4323986928","host_organization_name":"Zhongguo Yao Xuehui Shanghai Fenhui","host_organization_lineage":["https://openalex.org/P4323986928"],"host_organization_lineage_names":["Zhongguo Yao Xuehui Shanghai Fenhui"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Chinese Journal of New Drugs and Clinical Remedies","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1824070893","https://openalex.org/W2977936368","https://openalex.org/W3029386056","https://openalex.org/W2802963011","https://openalex.org/W963613765","https://openalex.org/W2377624160","https://openalex.org/W2545451733","https://openalex.org/W2094606482","https://openalex.org/W2363852307","https://openalex.org/W2887628796"],"abstract_inverted_index":{"AIM":[0],"To":[1],"evaluate":[2,75],"clinical":[3,63,91],"effect,":[4],"adverse":[5,66,94],"reaction,":[6],"and":[7,11,26,44,55,65,100,134,152,156],"pharmacoeconomics":[8],"of":[9,16,90,110,123,132,136,144,161],"gefitinib":[10,42,52,112,138,166],"erlotinib":[12,45,56,125,146,153],"in":[13,88,158],"the":[14,71,76,85,111,124,137,145,159],"treatment":[15,160],"non-small-cell":[17],"lung":[18],"cancer":[19],"(NSCLC).":[20],"METHODS":[21],"In":[22],"a":[23],"prospective":[24],"follow-up":[25],"retrospective":[27],"review":[28],"study,":[29],"100":[30],"patients":[31,48],"with":[32],"NSCLC":[33,163],"were":[34,49,68],"divided":[35],"into":[36],"2":[37],"groups":[38,73,87],"(n":[39],"=":[40],"50):":[41],"group":[43,113,126,139,147],"group.":[46],"The":[47,62],"given":[50],"respectively":[51],"(250":[53],"mg\u00b7d-1)":[54,58],"(150":[57],"till":[59],"disease":[60],"progression.":[61],"effect":[64,92,135],"reaction":[67,95],"compared":[69],"between":[70,84],"two":[72,86],"to":[74,103,142],"pharmacoeconomics.":[77],"RESULTS":[78],"There":[79],"was":[80,119,140],"no":[81],"significant":[82],"difference":[83],"term":[89],"rate,":[93,96,99],"one-year":[97],"survival":[98],"tumor\u2019s":[101],"time":[102],"progression":[104],"(TTP)":[105],"(P":[106,148],"0.05).":[107],"Average":[108],"cost":[109,133],"(16":[114],"542":[115],"\u00b1":[116,129],"s":[117],"184)":[118],"less":[120],"than":[121,170],"that":[122,143],"(19":[127],"714":[128],"209).":[130],"Ratio":[131],"superior":[141],"0.01).":[149],"CONCLUSION":[150],"Gefitinib":[151],"are":[154],"safe":[155],"effective":[157],"advanced":[162],"patients,":[164],"while":[165],"is":[167],"more":[168],"economic":[169],"erlotinib.":[171]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":2}],"updated_date":"2025-10-10T17:16:08.811792","created_date":"2016-06-24T00:00:00"}